|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Osteoporosis - Intermittent Dosing and Multiple Indications Drive Market Growth
Datamonitor, Jan 2004, Pages: 264
Introduction
Osteoporosis therapy has been largely focused on antiresorptive drugs that reduce the rate of bone loss. The condition is the focus of attention of significant R&D activity, with drugs in development both in existing classes offering advantages over marketed products and novel drugs exploiting genomics programs and a deeper understanding of bone biology.
Scope
Epidemiology of osteoporosis in the seven major markets by disease severity, identification of niche populations and unmet needs
Detailed profiles of drugs in Phase II and above. Analysis examines clinical data, patient potential, marketing factors, satisfaction of unmet needs
Primary research with key osteoporosis opinion leaders providing insight on future market entrants and innovative R&D projects in the disease area
Pharma Market Forecast model shows market potential with global sales forecasts for key pipeline drugs, currently marketed products and classes
Highlights
Novel bisphosphonates, Zometa and Boniva, with their novel dosing regimens and delivery methods, will lead growth in the osteoporosis market, as R&D osteoporosis drugs will reach sales of $4.7 billion by 2011.
Driven by new market leader Evista, which will lead Pfizer’s lasofoxifene and Wyeth’s bazedoxifene by targeting multiple indications, the SERMs drug class will be valued at $4.2 billion by 2011.
The osteoporosis early stage pipeline consists largely of drug candidates in new therapeutic classes, in particular cathepsin K inhibitors, osteoprotegerin and calcilytics. While these drugs have the potential to change the face of osteoporosis treatment in the long term, innovative approaches will likely be costly to patients, limiting potential.
Reasons to Purchase
Validate internal forecasts against drug/class sales model and assess market potential for pipeline products
Analyze competitive environment at time of product launch to inform best strategy for market entry
Highlight key R&D trends and company involvement in the market to inform licensing decisions and identify potential partners based on R&D activity
Region: Global
Customers who bought this item also bought
Drugs of Tomorrow: Osteoporosis - Will Bone Building Drugs Revolutionize the Market?
Pipeline Insight: Osteoporosis - Intermittent Dosing Drives Market Growth
Drugs of Tomorrow 2001: Stable Angina - An Unsatisfactory R&D Pipeline Facing Chronic Unmet Needs
Commercial Insight: Osteoporosis and HRT - HRT is down for the count, but can osteoporosis players pick up the pieces?
Commercial Insight: Osteoporosis and HRT - HRT is down for the count, but can osteoporosis players pick up the pieces?
Osteoporosis - The Science Of Compliance
Drugs of Tomorrow 2001: Anticoagulants - A pipeline flowing with future blockbusters
Drugs, Devices and Procedures of Tomorrow: Acute Stroke - Chasing the need for speed
Drugs of Tomorrow 2001: Diabetes
Strategic Perspectives 2001: Menopausal Disorders and Osteoporosis - Aging and Awareness Drive Market Growth
Osteoporosis - Novel Agents to Battle for Payer Acceptance
Drugs of Tomorrow 2002: Depression - A pipeline driven by side effect profile
|
|
|
|
